GMEDNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
GLOBUS MEDICAL INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$75.65−1.06 (-1.38%)
Close on Oct 19, 2026
- Market cap
- $10.39B
- P/E (TTM)
- 19.3
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
67.4%−5.0 pts over 5 years
Operating margin
16.3%+2.2 pts over 5 years
Net margin
18.3%+5.3 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +16.7% | +42.2% | +30.1% | +18.4% | |
| Gross profit | +33.5% | +37.7% | +28.2% | +17.0% | |
| Operating income | +189.1% | +28.2% | +33.9% | +10.8% | |
| Net income | +422.3% | +41.4% | +39.4% | +16.9% | |
| EPS, diluted | +422.7% | +28.4% | +31.2% | +12.9% | |
| Free cash flow | +45.3% | +78.0% | +34.2% | +23.2% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 13.5% | 7.0% | 12.3% | |
| Return on assets | 11.8% | 6.4% | 10.2% | |
| Current ratio | 6.43 | 6.80 | 4.26 | |
| Inventory turnover | 1.2× | 1.0× | 1.4× | |
| Capex to revenue | 7.3% | 8.1% | 5.6% | |
| Diluted shares | 96M | 101M | 137M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Globus Medical generated $1.97B from operations and spent $1.25B on capital expenditure, dividends and share buybacks. 39% of that went back into the business.
Generated
$1.97B
Used
$1.25B
Capital expenditure$489.33M39%Dividends$00%Share buybacks$756.29M61%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin18.3%
×Asset turnover0.56×
×Equity multiplier1.21×
=Return on equity, FY202512.3%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 18.3% | 0.56× | 1.21× | 12.3% |
| FY2024 | 4.1% | 0.49× | 1.26× | 2.5% |
| FY2023 | 7.8% | 0.44× | 1.23× | 4.2% |
| FY2022 | 18.6% | 0.51× | 1.12× | 10.6% |
| FY2021 | 15.6% | 0.53× | 1.12× | 9.2% |
| FY2020 | 13.0% | 0.49× | 1.10× | 7.0% |
| FY2019 | 19.8% | 0.55× | 1.09× | 12.0% |
| FY2018 | 21.9% | 0.60× | 1.10× | 14.5% |
| FY2017 | 16.9% | 0.63× | 1.11× | 11.9% |
| FY2016 | 18.5% | 0.64× | 1.14× | 13.5% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
8of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero$537.87M
- Cash generatingOperating cash flow above zero$753.45M
- Return on assets improvedROA up on the prior year2.0% → 10.2%
- Earnings backed by cashOperating cash flow above net income$753.45M vs $537.87M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose2.54 → 4.26
- No dilutionShare count did not rise138M → 137M
- Gross margin improvedGross margin up on the prior year58.90% → 67.41%
- More efficientAsset turnover rose0.50 → 0.56